Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
Open accessThe DOI matches its Crossref record; 150 of the 152 references it cites were found in a registry or an index.
Abstract
Immunotherapy has revolutionized the established therapeutics against tumors. As the major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable success in the treatment of malignancies. However, the clinical gains are far from universal and durable, because of the primary and secondary resistance of tumors to the therapy, or side effects induced by ICIs. There is an urgent need to find safe combinatorial strategies that enhance the response of ICIs for tumor treatment. Diets have an excellent safety profile and have been shown to play pleiotropic roles in tumor prevention, growth, invasion, and metastasis. Accumulating evidence suggests that dietary regimens bolster not only the tolerability but also the efficacy of tumor immunotherapy. In this review, we discussed the mechanisms by which tumor cells evade immune surveillance, focusing on describing the intrinsic and extrinsic mechanisms of resistance to ICIs. We also summarized the impacts of different diets and/or nutrients on the response to ICIs therapy. Combinatory treatments of ICIs therapy with optimized diet regimens own great potential to enhance the efficacy and durable response of ICIs against tumors, which should be routinely considered in clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, several factors, such as diet or concomitant drugs [8,9], were associated with changes in the gut microbiota composition and immune system functions, and their role in ICI efficacy modulation has yet to be fully elucidated.”
From A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · cited 1×
“Normally, inhibitory ICs act as the natural brakes of the human body via suppressing the body’s immune response and preventing the occurrence of autoimmunity [39].”
BackgroundThe diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971 · cited 1×
“As the representative of ICIs therapy, PD-1/PD-L1 or CTLA-4-based IC blockade therapy has been approved for treating multiple tumor types; however, the efficacy varies in different tumor types [41,42].”
BackgroundMyeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · cited 1×
“(3) Tumors can upregulate the expression of inhibitory ICs such as programmed cell death-ligand 1 (PD-L1), which binds to programmed cell death protein 1 (PD-l) on T cells and, thus, promotes peripheral T cell exhaustion [34,35].”
BackgroundTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329 · cited 1×
“ICIs are the blocking antibodies against inhibitory immune checkpoints (ICs) targeting the specific mechanisms that tumor cells employ to evade immune system detection [8].”
BackgroundPitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041 · cited 1×
“Extrinsic resistance occurs external to tumor cells throughout the T cell activation process, and the influencing factors include TME, host factors such age, genetic background, comorbidities, diet, use of antibiotics and steroids, metabolism, and gut microbiota [18,45,46].”
BackgroundCOLEY, W. B. (1893) · The American Journal of the Medical Sciences · doi:10.1097/00000441-189305000-00001 · Cited by 995
Vitamin C pharmacokinetics: Implications for oral and intravenous use
Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00010 · Cited by 992
Immunologic Effects of Vitamin D on Human Health and Disease
Charoenngam, N., & Holick, M. F. (2020) · Nutrients · doi:10.3390/nu12072097 · Cited by 967
COLEY, W. B. (1991) · PubMed · Cited by 965
Levine, M. E., Suarez, J. A., Brandhorst, S., Balasubramanian, P., Cheng, C.-W., Madia, F., Fontana, L., Mirisola, M. G., Guevara-Aguirre, J., Wan, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.02.006 · Cited by 910
The Health Benefits of Dietary Fibre
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2020) · Nutrients · doi:10.3390/nu12103209 · Cited by 892
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807 · cited 1×
“, breast and pancreas), the clinical efficacy of ICIs remains very limited [16,17].”
BackgroundVitamin C: The known and the unknown and Goldilocks
Padayatty, S., & Levine, M. (2016) · Oral Diseases · doi:10.1111/odi.12446 · Cited by 753
Bachem, A., Makhlouf, C., Binger, K. J., de Souza, D. P., Tull, D., Hochheiser, K., Whitney, P. G., Fernandez-Ruiz, D., Dähling, S., Kastenmüller, W., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.002 · Cited by 702
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653 · cited 2×
“The exact mechanisms include: (1) tumor neoantigen presentation, structure, and processing are genetically or epigenetically altered, which, thus, influences the activation of immune response and recruitment of effector T cells [7]; (2) alterations in the structure of MHC II/I due to gene defects affect antigen presen…”
BackgroundMoertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O'Connell, M. J., & Ames, M. M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198501173120301 · Cited by 637
Creagan, E. T., Moertel, C. G., O'Fallon, J. R., Schutt, A. J., O'Connell, M. J., Rubin, J., & Frytak, S. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909273011303 · Cited by 584
Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
COLSTON, K., COLSTON, M. J., & FELDMAN, D. (1981) · Endocrinology · doi:10.1210/endo-108-3-1083 · Cited by 558
Exploring vitamin D metabolism and function in cancer
Jeon, S.-M., & Shin, E.-A. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0038-9 · Cited by 550
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145207 · Cited by 533
Cameron, E., & Pauling, L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.9.4538 · Cited by 476
Ketogenic diet in the treatment of cancer – Where do we stand?
Weber, D. D., Aminzadeh-Gohari, S., Tulipan, J., Catalano, L., Feichtinger, R. G., & Kofler, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.026 · Cited by 464
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Coley, W. B. (1910) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591571000301601 · Cited by 423 · cited 1×
“The fields of immunology and oncology have been linked since the end of the 19th century when the surgeon William Coley [1,2] reported that an injection of attenuated bacteria into the sites of sarcoma led to tumor shrinkage.”
BackgroundDietary modifications for enhanced cancer therapy
Kanarek, N., Petrova, B., & Sabatini, D. M. (2020) · Nature · doi:10.1038/s41586-020-2124-0 · Cited by 411 · cited 2×
“Although the effects of certain dietary patterns and several nutrients (both macro- and micro-) on immunological outcomes and TME reprogramming have been extensively elucidated [21,23,24,26,47], not all of them were reported to associate with tumor immunotherapy efficacy.”
BackgroundNomura, M., Nagatomo, R., Doi, K., Shimizu, J., Baba, K., Saito, T., Matsumoto, S., Inoue, K., & Muto, M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.2895 · Cited by 396
Retinoids regulate stem cell differentiation
Gudas, L. J., & Wagner, J. A. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22417 · Cited by 395
Inflammation, vitamin B6 and related pathways
Ueland, P. M., McCann, A., Midttun, Ø., & Ulvik, A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.08.001 · Cited by 382
Retinoid pathway and cancer therapeutics
Bushue, N., & Wan, Y.-J. Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.003 · Cited by 373
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Ready, N., Farago, A. F., de Braud, F., Atmaca, A., Hellmann, M. D., Schneider, J. G., Spigel, D. R., Moreno, V., Chau, I., Hann, C. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.003 · Cited by 344 · cited 1×
“Despite the promising results of ICIs therapy in melanoma [9,10], urothelial carcinoma [11], lung tumors [12,13], colorectal tumors [14], and head and neck squamous cell carcinoma [15], clinical gains are far from universal.”
Immunometabolic Interplay in the Tumor Microenvironment
Kaymak, I., Williams, K. S., Cantor, J. R., & Jones, R. G. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.09.004 · Cited by 328 · cited 9×
“In murine sarcoma models, tumor-derived retinoic acid (RA) blocked monocyte differentiation into dendritic cells (DCs) within the TME to promote immune suppression, whilst blocking RA production in tumor cells or inhibiting RA signaling within the TME increased the percentage of immunostimulatory antigen-presenting ce…”
BackgroundInfluentialFukuda, R., Kelly, B., & Semenza, G. L. (2003) · PubMed · Cited by 326
Regulation of the epigenome by vitamin C
Young, J. I., Züchner, S., & Wang, G. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034228 · Cited by 319
High-dose vitamin C enhances cancer immunotherapy
Magrì, A., Germano, G., Lorenzato, A., Lamba, S., Chilà, R., Montone, M., Amodio, V., Ceruti, T., Sassi, F., Arena, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8707 · Cited by 285
Immunomodulatory and antimicrobial effects of vitamin C
Mousavi, S., Bereswill, S., & Heimesaat, M. M. (2019) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2019.00016 · Cited by 266
Devalaraja, S., To, T. K. J., Folkert, I. W., Natesan, R., Alam, M. Z., Li, M., Tada, Y., Budagyan, K., Dang, M. T., Zhai, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.042 · Cited by 257
Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
Dai, X., Bu, X., Gao, Y., Guo, J., Hu, J., Jiang, C., Zhang, Z., Xu, K., Duan, J., He, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.037 · Cited by 242
The influence of diet on anti-cancer immune responsiveness
Soldati, L., Di Renzo, L., Jirillo, E., Ascierto, P. A., Marincola, F. M., & De Lorenzo, A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1448-0 · Cited by 242 · cited 1×
“Although the effects of certain dietary patterns and several nutrients (both macro- and micro-) on immunological outcomes and TME reprogramming have been extensively elucidated [21,23,24,26,47], not all of them were reported to associate with tumor immunotherapy efficacy.”
BackgroundVitamin B6 in Health and Disease
Stach, K., Stach, W., & Augoff, K. (2021) · Nutrients · doi:10.3390/nu13093229 · Cited by 235
Clinical Evidence and Mechanisms of High-Protein Diet-Induced Weight Loss
Moon, J., & Koh, G. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20028 · Cited by 233
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
Xu, Y.-P., Lv, L., Liu, Y., Smith, M. D., Li, W.-C., Tan, X.-M., Cheng, M., Li, Z., Bovino, M., Aubé, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129317 · Cited by 228
Self-citationQian, D. C., Kleber, T., Brammer, B., Xu, K. M., Switchenko, J. M., Janopaul-Naylor, J. R., Zhong, J., Yushak, M. L., Harvey, R. D., Paulos, C. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00546-5 · Cited by 213 · cited 1×
“Despite the promising results of ICIs therapy in melanoma [9,10], urothelial carcinoma [11], lung tumors [12,13], colorectal tumors [14], and head and neck squamous cell carcinoma [15], clinical gains are far from universal.”
Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly
Shenoy, N., Creagan, E., Witzig, T., & Levine, M. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.014 · Cited by 205
Tobin, R. P., Jordan, K. R., Robinson, W. A., Davis, D., Borges, V. F., Gonzalez, R., Lewis, K. D., & McCarter, M. D. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.007 · Cited by 204
Verhoog, S., Taneri, P. E., Roa Díaz, Z. M., Marques-Vidal, P., Troup, J. P., Bally, L., Franco, O. H., Glisic, M., & Muka, T. (2019) · Nutrients · doi:10.3390/nu11071565 · Cited by 202
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3104 · Cited by 201
Optimal Diet Strategies for Weight Loss and Weight Loss Maintenance
Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20065 · Cited by 193
The Role of Dietary Protein Intake in the Prevention of Sarcopenia of Aging
Beasley, J. M., Shikany, J. M., & Thomson, C. A. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533613507607 · Cited by 191
Liao, C.-D., Chen, H.-C., Huang, S.-W., & Liou, T.-H. (2019) · Nutrients · doi:10.3390/nu11081713 · Cited by 189
Callahan, M. K., Kluger, H., Postow, M. A., Segal, N. H., Lesokhin, A., Atkins, M. B., Kirkwood, J. M., Krishnan, S., Bhore, R., Horak, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2850 · Cited by 186 · cited 1×
“Despite the promising results of ICIs therapy in melanoma [9,10], urothelial carcinoma [11], lung tumors [12,13], colorectal tumors [14], and head and neck squamous cell carcinoma [15], clinical gains are far from universal.”
Molecular Link between Vitamin D and Cancer Prevention
Moukayed, M., & Grant, W. (2013) · Nutrients · doi:10.3390/nu5103993 · Cited by 182
The Influence of Nutritional Factors on Immunological Outcomes
Tourkochristou, E., Triantos, C. K., & Mouzaki, Α. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665968 · Cited by 177 · cited 2×
“Although the effects of certain dietary patterns and several nutrients (both macro- and micro-) on immunological outcomes and TME reprogramming have been extensively elucidated [21,23,24,26,47], not all of them were reported to associate with tumor immunotherapy efficacy.”
BackgroundReinforce the antitumor activity of CD 8+ T cells via glutamine restriction
Nabe, S., Yamada, T., Suzuki, J., Toriyama, K., Yasuoka, T., Kuwahara, M., Shiraishi, A., Takenaka, K., Yasukawa, M., & Yamashita, M. (2018) · Cancer Science · doi:10.1111/cas.13827 · Cited by 175
Low-Protein Diet Induces IRE1α-Dependent Anticancer Immunosurveillance
Rubio‐Patiño, C., Bossowski, J. P., Donatis, G. M. D., Mondragón, L., Villa, E., Aira, L. E., Chiche, J., Mhaidly, R., Lebeaupin, C., Marchetti, S., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.009 · Cited by 174
Popular weight-loss diets: from evidence to practice
Malik, V., & Hu, F. B. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0726 · Cited by 169
The effects of vitamin B on the immune/cytokine network and their involvement in depression
Mikkelsen, K., Stojanovska, L., Prakash, M. D., & Apostolopoulos, V. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.11.012 · Cited by 168
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
Luchtel, R. A., Bhagat, T., Pradhan, K., Jacobs, W. R., Levine, M., Verma, A., & Shenoy, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908158117 · Cited by 167
Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment
Wu, X., Hu, W., Lu, L., Zhao, Y., Zhou, Y., Xiao, Z., Zhang, L., Zhang, H., Li, X., Li, W., et al. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.09.002 · Cited by 164
Self-citationEnhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet
Lussier, D. M., Woolf, E. C., Johnson, J. L., Brooks, K. S., Blattman, J. N., & Scheck, A. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2337-7 · Cited by 163
Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses
Galluzzi, L., Vacchelli, E., Michels, J., Garcia, P., Kepp, O., Senovilla, L., Vitale, I., & Kroemer, G. (2013) · Oncogene · doi:10.1038/onc.2012.623 · Cited by 150
Vitamin D and differentiation in cancer
Gocek, E., & Studzinski, G. P. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360902982128 · Cited by 140
Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Ferreira, R., Napoli, J., Enver, T., Bernardino, L., & Ferreira, L. (2020) · Nature Communications · doi:10.1038/s41467-020-18042-2 · Cited by 138
Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities
Talib, W. H., Mahmod, A. I., Kamal, A., Rashid, H. M., Alashqar, A. M. D., Khater, S. H., Jamal, D., & Waly, M. I. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43020042 · Cited by 135
Reduction of weight loss and tumour size in a cachexia model by a high fat diet
Tisdale, M., Brennan, R., & Fearon, K. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.149 · Cited by 132
Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Galluzzi, L., Vitale, I., Senovilla, L., Olaussen, K. A., Pinna, G., Eisenberg, T., Goubar, A., Martins, I., Michels, J., Kratassiouk, G., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.06.017 · Cited by 131
Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 129 · cited 9×
“In murine sarcoma models, tumor-derived retinoic acid (RA) blocked monocyte differentiation into dendritic cells (DCs) within the TME to promote immune suppression, whilst blocking RA production in tumor cells or inhibiting RA signaling within the TME increased the percentage of immunostimulatory antigen-presenting ce…”
BackgroundInfluentialDietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy
Orillion, A., Damayanti, N. P., Shen, L., Adelaiye-Ogala, R., Affronti, H., Elbanna, M., Chintala, S., Ciesielski, M., Fontana, L., Kao, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0980 · Cited by 121
Vitamin C as a Modulator of the Response to Cancer Therapy
Błaszczak, W., Barczak, W., Masternak, J., Kopczyński, P., Zhitkovich, A., & Rubiś, B. (2019) · Molecules · doi:10.3390/molecules24030453 · Cited by 119
An Update on Immunotherapy for Solid Tumors: A Review
Pham, T. D., Roth, S., Kong, J. C. H., Guerra, G., Narasimhan, V., Pereira, L. A., Desai, J., Heriot, A. G., & Ramsay, R. G. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6658-4 · Cited by 108 · cited 2×
“However, tumor cells can exploit this mechanism to escape the immune system by upregulating the expression of suppressive molecules that interact with T cells, rendering them incapable of killing [27].”
BackgroundVitamin D and Lung Cancer Risk: A Comprehensive Review and Meta-Analysis
Zhang, L., Wang, S., Che, X., & Li, X. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374072 · Cited by 103
Vitamin C – A new player in regulation of the cancer epigenome
Gillberg, L., Ørskov, A. D., Liu, M., Harsløf, L. B. S., Jones, P. A., & Grønbæk, K. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.001 · Cited by 100
Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy
Fan, C., Zhang, S., Gong, Z., Li, X., Xiang, B., Deng, H., Zhou, M., Li, Y., Li, Y., Xiong, W., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1735-4 · Cited by 99
Balachandar, R., Pullakhandam, R., Kulkarni, B., & Sachdev, H. S. (2021) · Nutrients · doi:10.3390/nu13103328 · Cited by 98
Doll and Peto's Quantitative Estimates of Cancer Risks: Holding Generally True for 35 Years
Blot, W. J., & Tarone, R. E. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv044 · Cited by 96
Lee, K. A., Shaw, H. M., Bataille, V. A., Nathan, P., & Spector, T. D. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.026 · Cited by 94 · cited 2×
“Moreover, some nutrients have been shown to play an important role in modulating immune functions [21,24,25].”
BackgroundIs dietary fibre truly protective against colon cancer? A systematic review and meta-analysis
Gianfredi, V., Salvatori, T., Villarini, M., Moretti, M., Nucci, D., & Realdon, S. (2018) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2018.1446917 · Cited by 93
Rossi, J., Céballos, P., & Lu, Z. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0379-3 · Cited by 93
Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells
Lee, S. J., Jeong, J., Lee, I. H., Lee, J., Jung, J. H., Park, H. Y., Lee, D. H., & Chae, Y. S. (2019) · Anticancer Research · doi:10.21873/anticanres.13172 · Cited by 92
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Chocarro de Erauso, L., Zuazo, M., Arasanz, H., Bocanegra, A., Hernandez, C., Fernandez, G., Garcia-Granda, M. J., Blanco, E., Vera, R., Kochan, G., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00441 · Cited by 91
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86 · cited 2×
“CAFs are the major components of the tumor stroma; they secrete cytokines, chemokines, inhibitory and extracellular matrix (ECM) remodeling molecules that suppress NK cell and cytotoxic T cell activity [38].”
BackgroundRetinoic Acid Receptors in Acute Myeloid Leukemia Therapy
di Martino, O., & Welch, J. S. (2019) · Cancers · doi:10.3390/cancers11121915 · Cited by 85
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
Wu, J., Wang, S., Zheng, B. J., Qiu, X., Wang, H., & Chen, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669150 · Cited by 83
Anti-Tumor Effects of Vitamin B2, B6 and B9 in Promonocytic Lymphoma Cells
Mikkelsen, K., Prakash, M. D., Kuol, N., Nurgali, K., Stojanovska, L., & Apostolopoulos, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153763 · Cited by 76
Flores, O., Wang, Z., Knudsen, K. E., & Burnstein, K. L. (2010) · Endocrinology · doi:10.1210/en.2009-1116 · Cited by 75
Chemoprevention of Breast Cancer With Vitamins and Micronutrients: A Concise Review
Mokbel, K., & Mokbel, K. (2019) · In Vivo · doi:10.21873/invivo.11568 · Cited by 74
Dobrotkova, V., Chlapek, P., Mazánek, P., Štěrba, J., & Veselská, R. (2018) · BMC Cancer · doi:10.1186/s12885-018-4966-5 · Cited by 73
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era
Spyrou, N., Vallianou, N. G., Kadillari, J., & Dalamaga, Μ. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.008 · Cited by 72
Rezasoltani, S., Yadegar, A., Aghdaei, H. A., & Zali, M. R. (2020) · Cancer Medicine · doi:10.1002/cam4.3694 · Cited by 72
Abdin, S. M., Zaher, D. M., Arafa, E. A., & Omar, H. A. (2018) · Cancers · doi:10.3390/cancers10020032 · Cited by 72
Tabassum, A., Samdani, M. N., Dhali, T. C., Alam, R., Ahammad, F., Samad, A., & Karpiński, T. M. M. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02088-w · Cited by 72 · cited 1×
“(1) Loss or alteration of specific antigens or antigenic machinery [28,29].”
BackgroundProtein restriction and cancer
Yin, J., Ren, W., Huang, X., Li, T., & Yin, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.03.004 · Cited by 69
Impact of Lifestyle Behaviors on Cancer Risk and Prevention
Choi, J.-W., & Hua, T. N. M. (2021) · Journal of Lifestyle Medicine · doi:10.15280/jlm.2021.11.1.1 · Cited by 69
Randrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
Katagiri, R., Goto, A., Sawada, N., Yamaji, T., Iwasaki, M., Noda, M., Iso, H., & Tsugane, S. (2020) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa002 · Cited by 64
Dimitrov, V., Bouttier, M., Boukhaled, G. M., Salehi-Tabar, R., Avramescu, R. G., Memari, B., Hasaj, B., Lukács, G. L., Krawczyk, C. M., & White, J. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.793885 · Cited by 64
Rom‐Jurek, E., Kirchhammer, N., Ugocsai, P., Ortmann, O., Wege, A. K., & Brockhoff, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020563 · Cited by 63
Spencer, C. N., Gopalakrishnan, V., McQuade, J., Andrews, M. C., Helmink, B., Khan, M. A. W., Sirmans, E., Haydu, L., Cogdill, A., Burton, E., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-2838 · Cited by 60
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 59 · cited 3×
“Extrinsic resistance occurs external to tumor cells throughout the T cell activation process, and the influencing factors include TME, host factors such age, genetic background, comorbidities, diet, use of antibiotics and steroids, metabolism, and gut microbiota [18,45,46].”
BackgroundWang, H., Zhao, Q., Zhang, Y., Zhang, Q., Zheng, Z., Liu, S., Liu, Z., Meng, L., Xin, Y., & Jiang, X. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652054 · Cited by 52 · cited 1×
“Despite the promising results of ICIs therapy in melanoma [9,10], urothelial carcinoma [11], lung tumors [12,13], colorectal tumors [14], and head and neck squamous cell carcinoma [15], clinical gains are far from universal.”
Nucci, D., Fatigoni, C., Salvatori, T., Nardi, M., Realdon, S., & Gianfredi, V. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18084168 · Cited by 51
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47 · cited 1×
“As the representative of ICIs therapy, PD-1/PD-L1 or CTLA-4-based IC blockade therapy has been approved for treating multiple tumor types; however, the efficacy varies in different tumor types [41,42].”
BackgroundGianfredi, V., Nucci, D., Salvatori, T., Dallagiacoma, G., Fatigoni, C., Moretti, M., & Realdon, S. (2019) · Nutrients · doi:10.3390/nu11071579 · Cited by 45
Zhou, Y., Zhang, Y., Guo, G., Cai, X., Yu, H., Cai, Y., Zhang, B., Hong, S., & Zhang, L. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.14 · Cited by 43 · cited 1×
“Despite the promising results of ICIs therapy in melanoma [9,10], urothelial carcinoma [11], lung tumors [12,13], colorectal tumors [14], and head and neck squamous cell carcinoma [15], clinical gains are far from universal.”
Gong, J., Hendifar, A. E., Tuli, R., Chuang, J., Cho, M. T., Chung, V. M., Li, D., & Salgia, R. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0210-9 · Cited by 42 · cited 1×
“, breast and pancreas), the clinical efficacy of ICIs remains very limited [16,17].”
BackgroundStucci, L. S., D’Oronzo, S., Tucci, M., Macerollo, A., Ribero, S., Spagnolo, F., Marra, E., Picasso, V., Orgiano, L., Marconcini, R., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.016 · Cited by 42
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 42 · cited 1×
“For example, the binding of PD-L1 expressed by tumor cells to PD-1 on the surface of TILs weakens the immune role of T cells, which causes tumor immune escape and promotes tumor progression [40].”
BackgroundField, S., Davies, J., Bishop, D. T., & Newton‐Bishop, J. (2013) · Dermato-Endocrinology · doi:10.4161/derm.25244 · Cited by 39
Sasso, A., & Latella, G. (2017) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2017.1393503 · Cited by 38
Insulin, carbohydrate restriction, metabolic syndrome and cancer
Fine, E. J., & Feinman, R. D. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.960392 · Cited by 37
Tratnjek, L., Jeruc, J., Romih, R., & Zupančič, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073510 · Cited by 37
Tsongalis, G. (2019) · Molecular and translational medicine · doi:10.1007/978-3-030-21540-8 · Cited by 35
Massive doses of vitamin C and the virus diseases
KLENNER, F. R. (1951) · PubMed · doi:10.5281/zenodo.10932887 · Cited by 34
Abreu y Abreu, A. T., Milke-García, M. P., Argüello-Arévalo, G. A., Calderón-de la Barca, A. M., Carmona-Sánchez, R. I., Consuelo-Sánchez, A., Coss-Adame, E., García-Cedillo, M. F., Hernández-Rosiles, V., Icaza-Chávez, M. E., et al. (2021) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2021.02.002 · Cited by 32
Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy
Yang, Y., Lu, X., Liu, Q., Dai, Y., Zhu, X., Wen, Y., Xu, J., Lu, Y., Zhao, D., Chen, X., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.038 · Cited by 32
Trace elements under the spotlight: A powerful nutritional tool in cancer
Rodríguez‐Tomàs, E., Baiges‐Gayà, G., Castañé, H., Arenas, M., Camps, J., & Joven, J. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126858 · Cited by 32 · cited 1×
“Although the effects of certain dietary patterns and several nutrients (both macro- and micro-) on immunological outcomes and TME reprogramming have been extensively elucidated [21,23,24,26,47], not all of them were reported to associate with tumor immunotherapy efficacy.”
BackgroundVitamin D increases programmed death receptor-1 expression in Crohn’s disease
Bendix, M., Greisen, S. R., Dige, A. K., Hvas, C. L., Fuglsang, N. F. B., Jørgensen, S. P., Dahlerup, J. F., Deleuran, B. W., & Agnholt, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.15489 · Cited by 32
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 31
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martín-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 28 · cited 2×
“Regarding the important roles of nutrients in modulating immune functions and influencing tumor growth and/or responsiveness to immune modulation [45], many dietary regimes are currently being explored in order to enhance the immunotherapy responses in tumor treatments [31].”
BackgroundBober, P., Alexovič, M., Talian, I., Tomková, Z., Viscorova, Z., Bencková, M., Andrašina, I., Ciccocioppo, R., Petrovič, D., Adamek, M., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2259-4 · Cited by 28
Vitamin A and its natural derivatives
Redfern, C. P. F. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2020.02.002 · Cited by 27
Nutrition and Cancer Risk from the Viewpoint of the Intestinal Microbiome
Tanaka, Y., Shimizu, S., Shirotani, M., Yorozu, K., Kitamura, K., Oehorumu, M., Kawai, Y., & Fukuzawa, Y. (2021) · Nutrients · doi:10.3390/nu13103326 · Cited by 23
Factor H in the Nutrition of Trout
McCay, C. M., Bing, F. C., & Dilley, W. E. (1928) · Science · doi:10.1126/science.67.1731.249 · Cited by 22
Attari, V. E., Panahi, G., Hébert, J. R., Ostadrahimi, A., Saghafi‐Asl, M., Yagin, N. L., & Baradaran, B. (2021) · Health Promotion Perspectives · doi:10.34172/hpp.2021.17 · Cited by 22
Zeng, T., Fang, X., Lu, J., Zhong, Y., Lin, X., Lin, Z., Wang, N., Jiang, J., & Lin, S. (2021) · International Journal of Colorectal Disease · doi:10.1007/s00384-021-04028-z · Cited by 22 · cited 1×
“Despite the promising results of ICIs therapy in melanoma [9,10], urothelial carcinoma [11], lung tumors [12,13], colorectal tumors [14], and head and neck squamous cell carcinoma [15], clinical gains are far from universal.”
Chen, X., He, M., & Zhou, G. (2019) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12931 · Cited by 22
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
Cruz‐Bermúdez, A., Briviesca, R. L., Casarrubios, M., Sierra‐Rodero, B., & Provencio, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040361 · Cited by 22
Hargadon, K. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20608 · Cited by 20 · cited 1×
“The exact mechanisms include: (1) tumor neoantigen presentation, structure, and processing are genetically or epigenetically altered, which, thus, influences the activation of immune response and recruitment of effector T cells [7]; (2) alterations in the structure of MHC II/I due to gene defects affect antigen presen…”
BackgroundNight blindness and ancient remedy
Binali, H. A. H. A. (2014) · Heart Views · doi:10.4103/1995-705x.151098 · Cited by 19
Embracing cancer immunotherapy with vital micronutrients
Yuen, R. C.-F., & Tsao, S. Y. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i9.712 · Cited by 18 · cited 2×
“Although the effects of certain dietary patterns and several nutrients (both macro- and micro-) on immunological outcomes and TME reprogramming have been extensively elucidated [21,23,24,26,47], not all of them were reported to associate with tumor immunotherapy efficacy.”
BackgroundIdentification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy
Yuan, J., Li, J., Shang, M., Fu, Y., & Wang, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.022 · Cited by 18
Gut Microbiota, the Immune System, and Cytotoxic T Lymphocytes
Cosola, C., Rocchetti, M. T., & Gesualdo, L. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1507-2_16 · Cited by 18
Massive doses of vitamin C and the virus diseases
Klenner, F. R. (1951) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.14495005 · Cited by 17
Vitamin D supplementation: a potential therapeutic agent for metastatic colorectal cancer
Yuan, C., & Ng, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0958-8 · Cited by 15
Qi, Y. A., Maity, T. K., Gao, S., Gong, T., Bahta, M., Venugopalan, A. K., Zhang, X., & Guha, U. (2021) · Cancers · doi:10.3390/cancers13194977 · Cited by 14 · cited 1×
“(1) Loss or alteration of specific antigens or antigenic machinery [28,29].”
BackgroundSelf-citationGut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy
Tian, M., Zhang, S., Tseng, Y., Shen, X., Dong, L., & Xue, R. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210706110713 · Cited by 12
Zhang, Y., Du, Z., Ma, W., Chang, K., & Zheng, C. (2020) · PubMed · doi:10.6133/apjcn.202009_29(3).0016 · Cited by 9
Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
Rizzo, M., Giannatempo, P., & Porta, C. (2021) · Biologics · doi:10.2147/btt.s290311 · Cited by 6 · cited 1×
“Despite the promising results of ICIs therapy in melanoma [9,10], urothelial carcinoma [11], lung tumors [12,13], colorectal tumors [14], and head and neck squamous cell carcinoma [15], clinical gains are far from universal.”
ResultLi, Z., Yang, G. N., Zhou, S., Wang, X., & Li, X. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-19-c065 · Cited by 4
Ozaki, Y., Suzuki, Y., Nishiyama, K., Suzutani, T., & Suzuki, H. (2021) · PubMed · Cited by 3
Research works printed but not linked: 1
- Xing, 2021, Advances in research on tumor immunotherapy and its drug development, J. China Pharm. Univ., 52, 10
Cited by
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential
Xiao, Y.-L., Gong, Y., Qi, Y.-J., Shao, Z.-M., & Jiang, Y.-Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01771-x · Cited by 202
“140 A traditional KD is typically formulated at a 4:1 ratio of fat:carbohydrate plus protein.”
BackgroundYu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40
“Additionally, there are studies indicating that the microbiome [53,54] and diet [55] can alter tumor responses to ICIs.”
BackgroundMarhold, M., Udovica, S., Halstead, A., Hirdler, M., Ferner, M., Wimmer, K., Bagó-Horváth, Z., Exner, R., Fitzal, F., Strasser‐Weippl, K., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2275846 · Cited by 40
Pietrzak, B., Tomela, K., Olejnik-Schmidt, A., Galus, Ł., Mackiewicz, J., Kaczmarek, M., Mackiewicz, A., & Schmidt, M. (2022) · Cancers · doi:10.3390/cancers14215369 · Cited by 36
“Moreover, several factors, such as diet or concomitant drugs [8,9], were associated with changes in the gut microbiota composition and immune system functions, and their role in ICI efficacy modulation has yet to be fully elucidated.”
BackgroundDuttagupta, S., Hakozaki, T., Routy, B., & Messaoudene, M. (2023) · Current Oncology · doi:10.3390/curroncol30110681 · Cited by 31
“Ketogenic diet and a protein-restricted diet have both shown a reduction in PD-1, PD-L1, and CTLA-4 expressions and increased the efficacy of ICI treatments in animal models [82].”
Background
Metadata
- Authors
- Zhang, X., Li, H., Lv, X., Hu, L., Li, W., Zi, M., & He, Y.
- Affiliations
- First Affiliated Hospital of Dalian Medical University (CN)
- Kunming Institute of Zoology (CN)
- State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650201, China
- Third People's Hospital of Yunnan Province (CN)
- Corresponding author
- He, Yonghan
- Venue
- Life
- Publisher
- MDPI AG
- Published
- 2022-03-11
- Volume
- 12
- Issue
- 3
- Pages
- 409
- ISSN
- 2075-1729 (ISSN-L)
- PMC
- PMC8951256
- OpenAlex
- W4221004391
- Cited by
- 18
- References
- 152
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 2
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Life (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Applied Basic Research Projects of Yunnan Province (202101AS070137, 202101BA070001-110)
- National Natural Science Foundation of China (82171558)
- Strategic Priority Research Program of the Chinese Academy of Sciences (XDPB17)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitors, diet, cancer immunotherapy, immunotherapy resistance, tumor immune evasion, immune surveillance, nutrients, combination therapy, cancer treatment side effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.